Andrew R. Swartz
Papers
1
Total Citations
6
H-Index
1
About
Andrew R. Swartz is a bioprocess scientist whose work sits at the critical intersection of analytical method development and next-generation vaccine manufacturing. His primary research focuses on the characterization and quality control of mRNA-based therapeutics, with a particular emphasis on detecting process-related impurities that can compromise product safety and efficacy. Swartz’s most notable contribution is the development and application of an automated sandwich ELISA for the quantitation of residual double-stranded RNA (dsRNA) in mRNA vaccines—a breakthrough impurity that arises as a byproduct of in vitro transcription. This work, published in 2024 and already garnering 6 citations, addresses a pressing regulatory and manufacturing challenge as mRNA platforms rapidly scale to confront global disease. By enabling robust, high-throughput detection of dsRNA, Swartz’s method directly supports the production of safer, more potent vaccines. His research is foundational for ensuring that novel mRNA therapies meet rigorous quality standards, making him a key figure in the translation of laboratory innovation into real-world clinical impact.
Research Focus
Key Achievements
Top Papers
- 1